Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials

10 Apr 2013

Abstract excerpt

BACKGROUND: Telaprevir (TVR), a hepatitis C virus (HCV) NS3/4A protease inhibitor, has been approved to treat genotype 1 HCV. To understand the clinical impact of TVR-resistant variants, we analyzed samples from patients in phase 3 clinical trials to determine the frequency and retention of TVR-resistant variants in patients who did not achieve sustained virologic response (SVR). METHODS: A total of 1797 patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiplatelet Therapy and Cardiovascular Diseases
Share to Hepatitis C virus research
Share to HIV/AIDS drug development and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23575197
DOI: 10.1093/cid/cit226

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical TrialsPMID 23575197Read ↗

Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.Semantic proximity Read ↗

Deep-Sequencing Analysis of the Gene Encoding the Hepatitis C Virus Nonstructural 3–4A Protease Confirms a Low Prevalence of Telaprevir-Resistant Variants at Baseline and the End of the REALIZE StudySemantic proximity Read ↗

Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy.Semantic proximity Read ↗

Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.Semantic proximity Read ↗

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.Semantic proximity Read ↗

Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection.Semantic proximity Read ↗

Baseline and post-treatment hepatitis C NS5A resistance in relapsed patients from a multicentric real-life cohort.Semantic proximity Read ↗

Evaluation of Persistence of Resistant Variants with Ultra-Deep Pyrosequencing in Chronic Hepatitis C Patients Treated with TelaprevirSemantic proximity Read ↗

Incidence of virological failure and emergence of resistance with twice-daily vs every 8-h administration of telaprevir in the OPTIMIZE study.Semantic proximity Read ↗

Rapid emergence of protease inhibitor resistance in hepatitis C virus.Semantic proximity Read ↗

8 EVOLUTION OF TREATMENT-EMERGENT RESISTANT VARIANTS IN TELAPREVIR PHASE 3 CLINICAL TRIALSSemantic proximity Read ↗

Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.